Subsequently, an expanded trial of 460 patients revealed that a high number of stroke patients received tissue plasminogen activator (TPA) and that there was a significant increase in overall death rate with EPO treatment (42/256) compared with the placebo group (24/266) [184]. The gene discussed is EPO; the disease is Stroke.